



SUPPLEMENTARY FIG. S3. CCL5 upregulation after AAV2-hASM infusion. Brain homogenates of thalamic punches indicated an elevation in CCL5 in the high-dose vector-treated NHPs as compared with controls. Detection of this chemokine was most prominent in the 3-month survival group ($n=2$ per group). Note a reduction in CCL5 levels in the 9-month treatment group.